Pharma News
04 Jan 2026 to 10 Jan 2026
Jan 10, 2026
A Leading Retailer to Offer the New Wegovy Medication at a Monthly Price of $149 | The Healthy
Novo Nordisk has announced the launch of the first oral prescription for Wegovy, a GLP-1 medication, available at Sam’s Club starting January 12. The once-daily 1.5-milligram pill will cost $149 per month. Wegovy, a semaglutide, aids in weight loss and reduces risks associated with obesity and heart disease, following a successful clinical trial showing significant weight loss.
Jan 10, 2026
The Leading GLP-1 Manufacturer Expands Its Advantage as the Versatile Healthcare Corporation Reports ...
Eli Lilly reported a remarkable 53.9% revenue growth and a 480% increase in net income, driven by strong demand for its GLP-1 drugs, Mounjaro and Zepbound. In contrast, Johnson & Johnson achieved 6.8% revenue growth with a diversified portfolio. Lilly's operating margin reached 48.3%, while J&J's was 30.2%. Novo Nordisk's upcoming oral Wegovy poses new competition for Lilly.
Jan 10, 2026
US FDA Establishes Stringent Regulations for Importing Liquid Cough and Cold Medications from India
The US FDA has issued strict guidelines for importing liquid cough and cold medicines from India due to concerns over diethylene glycol (DEG) and ethylene glycol (EG) contamination. The new regulations require rigorous testing and documentation from importers to ensure safety and compliance.
Jan 10, 2026
The Effects of Discontinuing Weight Loss Injections - Health and Me
A study reveals that individuals who lose weight with GLP-1 drugs like Ozempic may regain all lost weight within two years of discontinuation. Additionally, heart health risk factors, including blood pressure and cholesterol, are expected to revert to pre-treatment levels within 1.4 years after stopping the medication.
Jan 10, 2026
Ipsen Addresses Global Supply Issues for Lanreotide Generics
Ipsen has acknowledged potential challenges in the manufacturing and availability of generic lanreotide, assuring that it can supply Somatuline (60mg, 90mg, 120mg) to meet patient needs. The company is monitoring the situation and will provide guidance for 2026 alongside its 2025 results on February 12. Ensuring patient access remains Ipsen's top priority.
Jan 10, 2026
The pastry chef who developed a patented anti-cancer compound that has been acquired for more than $8 billion.
Eduard Batlle, a biologist and one of the inventors of petosemtamab, has seen his experimental cancer treatment acquired by Danish company Genmab for approximately €7 billion ($8.2 billion). Initial trials show promise, particularly in treating head and neck cancer, with a significant percentage of participants responding positively. Petosemtamab targets cancer stem cells, marking a potential breakthrough in oncology.
Jan 10, 2026
Worldwide Pain Intensity; Tertiary Patents for FDA-Authorized Medications | MedPage Today
This week's TTHealthWatch podcast discusses global pain prevalence, highlighting a study showing increased pain levels in 15 countries. It also examines tertiary patents on FDA-approved drugs, which prolong patent protection and hinder generic competition. Additionally, age-specific D-dimer cutoffs for diagnosing deep vein thrombosis (DVT) are proposed, and a study links infant screen time to increased anxiety in adolescents.
Jan 9, 2026
US lawsuits increase over migraine medications and disputes regarding COVID vaccines | Americas
A recent dispute in the med tech industry has highlighted critical questions regarding when companies should respond to suspicions of theft and the potential for damages to accumulate alongside injunctions. This case is expected to have significant implications for the sector.
Jan 9, 2026
Trends Influencing the Future of the Generic Pharmaceuticals Market - PharmiWeb.com
The global Generic Drugs Market is projected to grow from USD 487.21 billion in 2024 to USD 898 billion by 2035, driven by rising healthcare costs and patent expirations. Key players include Mylan N.V., Teva Pharmaceutical Industries, and Pfizer Inc. The market faces challenges like regulatory hurdles but benefits from trends such as biosimilars and online pharmacies.
Jan 9, 2026
Eli Lilly and JD.com have been featured as Zacks' Bull and Bear of the Day, according to TradingView.
Eli Lilly and Co. (LLY) has been named the Bull of the Day by Zacks Equity Research, driven by strong sales from obesity drugs Mounjaro and Zepbound, which generated $24.8 billion in 2025. The company is expanding its obesity drug access through a deal with the Trump Administration. Meanwhile, JD.com (JD) is highlighted as the Bear of the Day due to declining sales growth.
Jan 9, 2026
Lilly expands its portfolio beyond major obesity medications by acquiring Ventyx for $1.2 billion.
Eli Lilly (LLY) has announced its acquisition of Ventyx Biosciences (VTYX) for $1.2 billion in cash, aiming to enhance its portfolio beyond diabetes and weight-loss drugs. Ventyx is developing treatments for inflammatory bowel diseases and other conditions. The deal, expected to close in the first half of 2026, reflects Lilly's strategy to invest in transformative opportunities.
Jan 9, 2026
Anticipations for AbbVie's Immunology Division in the Fourth Quarter
AbbVie (ABBV) is experiencing growth in its immunology franchise, driven by strong sales of its blockbuster drugs, Skyrizi and Rinvoq, particularly in inflammatory bowel disease. The company is set to report Q4 2025 results on February 4, 2025, with estimated sales of $4.87 billion for Skyrizi and $2.33 billion for Rinvoq. Competitors include Johnson & Johnson (JNJ) and Eli Lilly (LLY).
Jan 9, 2026
Anticipations for AbbVie's Immunology Division in the Fourth Quarter - TradingView
AbbVie (ABBV) is experiencing growth in its immunology franchise, driven by strong sales of its blockbuster drugs, Skyrizi and Rinvoq, despite the loss of exclusivity for Humira. The company anticipates Q4 2025 sales of $4.87 billion for Skyrizi and $2.33 billion for Rinvoq. AbbVie is also expanding in neuroscience and oncology, competing with Johnson & Johnson (JNJ) and Eli Lilly (LLY).
Jan 9, 2026
Wegovy Weight Loss Medication Now Available in Pharmacies: Key Information - Patch
Novo Nordisk's Wegovy, a GLP-1 weight-loss drug, is now available as a daily pill, making it more accessible and affordable for Americans seeking weight loss. Priced at $149 to $299 monthly, it offers similar efficacy to its injectable counterpart. However, experts caution about potential side effects and emphasize that it should be part of a comprehensive treatment plan.
Jan 9, 2026
Stock of the Day: Eli Lilly (LLY) - The Globe and Mail
Eli Lilly and Company (LLY) continues to thrive with its obesity drugs Mounjaro and Zepbound, generating combined sales of $24.8 billion in 2025. The company has partnered with the Trump Administration to enhance access to obesity treatments through the “BALANCE” program. With a strong pipeline and robust growth projections, LLY is positioned for sustained success in the pharmaceutical market.
Jan 9, 2026
AnaptysBio Seeks to Dismiss GSK/Tesaro's Rejection of Jemperli Royalty Claims
AnaptysBio has filed a motion to dismiss a breach claim from TESARO, Inc., now owned by GlaxoSmithKline, regarding royalties from the cancer drug Jemperli (dostarlimab). The dispute, stemming from a 2014 agreement, could impact drug pricing and biotech funding. A trial is set for July 2026, with market reactions already affecting AnaptysBio's stock.
Jan 9, 2026
Pharmaceutical Partnerships Increase as Sector Moves Past Trump-Related Concerns - Bloomberg
Drugmakers are heading to the JPMorgan Healthcare Conference in San Francisco next week with increased confidence compared to 2025, as uncertainties surrounding drug pricing and tariffs under President Donald Trump have diminished.
Jan 9, 2026
India Escalates Efforts to Combat Illegal Drugs and Prohibited Medications Across the Country
Law enforcement agencies in India have intensified operations against the smuggling and sale of narcotics, including codeine-based cough syrups and counterfeit medicines. Recent raids have led to multiple arrests across various states, highlighting the government's crackdown on illegal drug activities.
Jan 9, 2026
Is Bristol Myers Squibb (BMY) Subtly Shifting Its Narrative After Patent Expiration with Opdivo and ...
Bristol-Myers Squibb has received approval for a new subcutaneous formulation of Opdivo and advanced its KarXT autism program. The company also reached an agreement to supply Eliquis free to Medicaid while donating its active ingredient to a government reserve. These initiatives aim to bolster growth amid upcoming patent expiries and enhance its pediatric neuropsychiatry focus.
Jan 9, 2026
S&P report emphasizes the concentration risk faced by major pharmaceutical companies during the surge of deals leading up to JPMorgan's conference.
Merck's revenue heavily relies on Keytruda, which faces loss of exclusivity by 2028, raising concerns about concentration risk, according to S&P Global Ratings. Similarly, Novo Nordisk's revenue is largely dependent on semaglutide. The report highlights the need for continuous R&D investment, as U.S. companies are increasingly focusing on acquisitions to sustain growth amid regulatory risks.
Jan 9, 2026
Merck Plans Acquisition of Cancer Treatment Company Revolution Medicines as Keytruda Approaches Patent Expiration
Merck (MRK) is reportedly pursuing an acquisition of Revolution Medicines (RVMD), a biotech focused on therapies for RAS-addicted cancers. While a deal is not finalized and may take weeks, interest from other pharmaceutical companies complicates the situation. RVMD shares surged 18% after hours, while MRK shares saw a slight decline. Merck aims to strengthen its portfolio ahead of Keytruda's patent expiration in 2028.
Jan 9, 2026
Newron obtains important European patent for its schizophrenia medication Evenamide.
Newron Pharmaceuticals has received an additional patent from the European Patent Office for its lead compound, evenamide, covering its crystalline forms and therapeutic uses until 2044. This patent strengthens Newron's intellectual property strategy and supports evenamide's potential as the first add-on therapy for treatment-resistant schizophrenia, addressing a significant unmet need in patient care.
Jan 8, 2026
Research reveals the rapid weight regain following the discontinuation of weight-loss medications - RFI
Recent research reveals that individuals who stop using GLP-1 agonists, such as Novo Nordisk's Ozempic and Wegovy, regain weight four times faster than those who cease diet and exercise programs. The study indicates that participants regained 10 kg within a year after discontinuing these drugs, highlighting the need for ongoing treatment in obesity management.
Jan 8, 2026
Biotech company Alveus secures $160 million to address weight loss sustainability.
Alveus Therapeutics has secured $159.8 million in funding to develop long-term obesity treatments, addressing the high dropout rates of current therapies. The Series A round was led by New Rhein Healthcare Investors and includes Sanofi Capital. Alveus is focusing on ALV-100, which combines GLP-1 activation with GIP receptor blocking, and ALV-200, an amylin-based therapy.
Jan 8, 2026
Could peptide medications be the sole solution for the multi-billion dollar weight loss industry?
The global market for anti-obesity drugs reached $6 billion in 2023, with Goldman Sachs predicting a rise to $100 billion by 2030. The glucagon-like peptide-1 receptor (GLP-1R) is a key target for diabetes and obesity treatments. Notable developments include Gmax Biopharm's Glutazumab and Regeneron's antibody-tethered drug conjugates, enhancing treatment efficacy and safety.
Jan 8, 2026
Uttar Pradesh to Initiate Comprehensive Review of Wholesale Pharmaceutical Distributors and Storage Facilities
The Uttar Pradesh government is set to launch a month-long scrutiny of wholesale drug dealers and warehouses to combat the issue of spurious and misused drugs. This initiative follows a recent scandal involving codeine-based cough syrup, highlighting the need for stricter oversight in the pharmaceutical sector.
Jan 8, 2026
Biotech company Alveus secures $160 million to address weight loss sustainability.
Alveus Therapeutics has secured $159.8 million in Series A funding to develop long-term obesity treatments, addressing the high dropout rates of current therapies. The company is focusing on ALV-100, which combines GLP-1 activation and GIP receptor blocking, and ALV-200, an amylin-based therapy. The funding was led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds, with participation from Sanofi Capital.
Jan 8, 2026
Morning Briefing: The booming market for Ozempic alternatives - The Globe and Mail
Generic semaglutide has become legal in Canada, potentially reducing the price of Ozempic and Wegovy by up to 65%. Novo Nordisk, the maker of these weight-loss drugs, faces competition from generics and rivals like Eli Lilly's Mounjaro and Zepbound. The shift could significantly impact the market, benefiting consumers while challenging Novo Nordisk's profitability.
Jan 8, 2026
More affordable obesity treatments may be available in Canada this summer, according to Health ... - Radio-Canada
Health Canada is reviewing nine submissions for generic versions of semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, which could lower prices for these weight loss medications. Companies like Sandoz Canada, Apotex, and Teva Canada are among those applying. Experts suggest that cheaper alternatives may not be available until summer 2024, despite the potential for significant cost reductions.
Jan 8, 2026
Obesity Therapies Outperform Keytruda, Transforming the Market for Blockbuster Medications
Obesity treatments Mounjaro (Eli Lilly) and Wegovy (Novo Nordisk) surpassed Keytruda in global sales, reaching $35.8 billion and $35.6 billion, respectively. This marks a significant shift in the pharmaceutical landscape. The market is evolving towards oral formulations and combination therapies, with Eli Lilly collaborating with Nimbus Therapeutics to develop new oral treatments. Novo Nordisk is also pursuing amylin-based therapies.
Jan 8, 2026
Alveus Therapeutics Launches with $160 Million to Innovate Obesity Medications
Alveus Therapeutics has secured $159.8 million in financing to advance its obesity drug pipeline, led by ALV-100, which targets GLP-1 and blocks GIP. This approach aims to improve weight loss maintenance and tolerability compared to existing treatments like Eli Lilly's Zepbound. Alveus plans Phase 2 testing for ALV-100 and anticipates data by late 2027.
Jan 8, 2026
Research reveals the rapid weight regain following the discontinuation of weight-loss medications - France 24
A review of GLP-1 agonists, including Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, reveals that while these drugs can lead to significant weight loss, about half of users discontinue them within a year due to side effects or cost. Participants regained weight quickly after stopping, highlighting the need for ongoing treatment and comprehensive strategies for obesity management.
Jan 7, 2026
Lilly expands its portfolio beyond major obesity medications by acquiring Ventyx for $1.2 billion.
Eli Lilly is set to acquire Ventyx Biosciences for $1.2 billion, enhancing its portfolio beyond diabetes and weight-loss drugs. Ventyx is developing treatments for inflammatory bowel diseases and other disorders. The deal, priced at $14 per share, reflects Lilly's strategy to invest in transformative opportunities. The acquisition is expected to close in the first half of 2026.
Jan 7, 2026
Haisco Pharmaceutical secures patents for innovative antibody-drug conjugates - BioWorld
Haisco Pharmaceutical Group Co. Ltd. has patented new antibody-drug conjugates that combine antibodies with antitumor drugs via a linker, aiming to enhance cancer treatment efficacy.
Jan 7, 2026
Omeros sets the price of its drug for transplant complications at $36,000 for each dose - Yahoo! Finance Canada
Omeros has priced its newly approved drug Yartemlea at $36,000 per single-dose vial to treat transplant-associated thrombotic microangiopathy (TA-TMA) in patients aged two and older. The drug, a monoclonal antibody, blocks the MASP-2 protein and is the first approved treatment for TA-TMA. Omeros expects a decision from European regulators by mid-2026.
Jan 7, 2026
Lilly expands its portfolio beyond major obesity medications by acquiring Ventyx for $1.2 billion - Yahoo Finance
Eli Lilly is set to acquire Ventyx Biosciences for $1.2 billion, enhancing its portfolio beyond diabetes and weight-loss drugs. Ventyx is developing treatments for inflammatory bowel diseases and a cardiovascular condition linked to obesity. The deal, priced at $14 per share, is expected to close in the first half of 2026, following Lilly's record sales of GLP-1 drugs.
Jan 7, 2026
Government Evaluates Distinct Licensing System for Bulk Pharmaceuticals, Active Pharmaceutical Ingredients, and Key Starting Materials in ...
The government is considering a new licensing framework for bulk drugs, active pharmaceutical ingredients (APIs), and key starting materials (KSMs) to enhance regulatory oversight in the pharmaceutical sector. This initiative aims to improve traceability and quality control standards, although specific details and timelines remain undisclosed as officials assess its feasibility.
Jan 7, 2026
Popular Medications Could Hinder Innovation and Competition in the Pharmaceutical Industry
A recent article from "World of DTC Marketing" discusses how blockbuster drugs may hinder pharmaceutical innovation and competition. It highlights concerns over companies' reliance on single revenue streams, increased public scrutiny, and potential barriers for smaller firms. The piece emphasizes the need to balance profitability with long-term sustainability in the pharmaceutical industry.
Jan 7, 2026
GLP-1 medications set to receive FDA approval by 2026 - TechTarget
Eli Lilly and Novo Nordisk are vying for dominance in the GLP-1 market, projected to exceed $140 billion by 2030. Eli Lilly's orforglipron, a first-in-class oral GLP-1 therapy, is expected to receive FDA approval in 2026, offering a convenient alternative to existing treatments like Rybelsus and Wegovy. The competition is set to intensify as both companies innovate and expand their offerings.
Jan 7, 2026
Could the partnership for Lilly's Nimbus obesity medication change the perspective of Eli Lilly (LLY) investors?
Nimbus Therapeutics has entered a multi-year collaboration with Eli Lilly to develop a novel oral treatment for obesity and metabolic diseases. The agreement includes a $55 million upfront payment and potential total payments of $1.3 billion. This partnership enhances Lilly's oral obesity pipeline, particularly alongside its GLP-1 candidate, orforglipron, expected to receive regulatory approval by March 2026.
Jan 7, 2026
Natco Pharma contests the Wegovy patent held by Novo Nordisk, taking the matter to the Delhi High Court.
Natco Pharma has filed a petition in the Delhi High Court seeking the revocation of Indian Patent No. 262697 owned by Novo Nordisk A/S, related to the diabetes drug Semaglutide. The court has allowed Natco to submit additional documents and set timelines for responses from the respondents, including the Union of India.
Jan 7, 2026
Reform of Pharmaceutical Patents in the European Union - Mondaq
On December 11, 2025, the EU Council and Parliament reached a provisional agreement on the "pharma package," aimed at enhancing patient access to medicines, improving competitiveness, and addressing drug shortages. Key reforms include eight years of regulatory data protection, clarified "Bolar" exemptions, and a new transferable exclusivity voucher for antibiotics, addressing antimicrobial resistance.
Jan 6, 2026
The Reality of Formycon AG: A Biotech Dark Horse That May Surprise Major Pharmaceutical Companies
Formycon AG, a German biotech firm specializing in biosimilars, is gaining attention for its potential in the competitive market of biologic drugs. While currently under the radar, its stock (ISIN: DE000A1EWVY8) could see significant movement with key regulatory approvals or partnerships. Investors should consider its volatility and long-term prospects in the biosimilar sector.
Jan 6, 2026
Unlawful Distribution of Prohibited Allergy Medication Discovered in Rajasthan - Drugs Control Media Services
Authorities in Rajasthan have uncovered the illegal sale of Wincet-L tablets (Levocetirizine Dihydrochloride), a banned allergy medication. A pharmaceutical company from Himachal Pradesh defied a manufacturing ban, leading to the seizure of the drug stocks.
Jan 6, 2026
High Court Sends Notice to Novo Nordisk Regarding Natco Pharma's Request to Revoke Semaglutide Patent
Natco Pharma has made progress in its patent challenge against Novo Nordisk, as the High Court issued a notice regarding the revocation of the semaglutide patent. This legal development could pave the way for generic versions of the diabetes and weight management drug, impacting the pharmaceutical market in India. Novo Nordisk must now respond to Natco's allegations.
Jan 6, 2026
The expiration of the Semaglutide patent in India presents significant prospects for generic pharmaceutical manufacturers.
The impending patent expiry of semaglutide, a diabetes and obesity treatment by Novo Nordisk, is set to create significant opportunities for Indian pharmaceutical companies. Dr Reddy's and Sun Pharma are poised to lead launches in Canada and Brazil, respectively. Prices may drop 30-50%, boosting the Indian Pharmaceutical Market by 0.5-1%. Other players include Cipla, Zydus Lifesciences, and Biocon.
Jan 6, 2026
Mint Explainer: What motivates Indian pharmaceutical companies to contest the patents of international corporations?
Indian courts maintain a stringent yet fair stance on pharmaceutical patents, as demonstrated in the 2013 Novartis-Glivec ruling. Novartis AG's attempt to patent its cancer drug Glivec (imatinib mesylate) was denied due to insufficient evidence of therapeutic advancement, a decision reaffirmed by the Supreme Court to prevent evergreening while fostering genuine innovation.
Jan 6, 2026
Natco Pharma Requests Delhi High Court to Cancel Novo Nordisk's Patent for Semaglutide
Novo Nordisk is appealing rulings in a legal battle at the Delhi High Court, set for later this month. This comes as India's market for GLP-1 receptor agonists, used for treating type 2 diabetes and obesity, has surged from ₹186 crore in November 2022 to ₹1,047 crore by November 2025, according to Pharmarack data.
Jan 6, 2026
Amgen Acquires Cancer Treatment Company Dark Blue for $840 Million - Bloomberg.com
Amgen Inc. has acquired Dark Blue Therapeutics Ltd. for up to $840 million, enhancing its oncology portfolio. Dark Blue, based in the UK, is developing protein degraders, a promising drug class. Its lead compound aims to provide a novel treatment for acute myeloid leukemia, a rapidly progressing blood cancer.
Jan 6, 2026
Should Investors Worry About the Recent Clinical Trial Results from This Major Pharmaceutical Company?
Novo Nordisk has launched a pill version of its GLP-1 weight loss drug, becoming the first to market with this formulation. However, the company faced setbacks with a failed trial assessing the drug's effects on Alzheimer's. Despite the challenges, some experts suggest potential future benefits from the trial data. Eli Lilly and Pfizer are also developing competing GLP-1 products.
Jan 6, 2026
The Rising Popularity of GLP-1: A Transformative Shift in the Connection Between Humans and Medications
Novo Nordisk's Semaglutide, a GLP-1 receptor agonist, has surged to become the world's top-selling drug, surpassing traditional blockbuster medications. With over $10 billion in sales in the first half of the year, its success reflects a shift towards comprehensive metabolic management and proactive health. The pharmaceutical industry is now focusing on weight-loss and metabolic drugs, redefining health management strategies.
Jan 6, 2026
Clarivate Recognizes Eleven Promising Blockbuster and Game-Changing Treatments for 2026...
Clarivate Plc's 2026 Drugs to Watch report highlights eleven therapies anticipated to significantly impact patient care in weight loss, diabetes, oncology, and rare conditions. These therapies are expected to achieve blockbuster status and transform treatment approaches within five years, reinforcing the report's role as a key reference for pharmaceutical innovation.
Jan 6, 2026
More affordable obesity treatments may be available in Canada this summer, according to Health Canada... - CBC
Health Canada is reviewing nine submissions for generic versions of semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, which could lower prices for these weight loss medications. Experts suggest that while Canada may become the first country to offer cheaper versions, approvals are unlikely before summer 2024. Companies like Sandoz, Apotex, and Teva are among those applying.
Jan 6, 2026
Wegovy's initial dosage is now offered as a daily pill rather than a weekly injection - WSVN
Novo Nordisk has launched the oral version of its weight-loss drug Wegovy, available in a 1.5 mg starter dose for $149 monthly. The pill, which uses semaglutide, is expected to provide similar weight loss results as the injection. Eli Lilly is also developing an oral GLP-1 medication, orforglipron, anticipated for FDA approval by summer.
Jan 6, 2026
Roche invests $100 million to maintain the integrity of its GLP-1 structure - Fierce Biotech
Roche has secured a $100 million license from Structure Therapeutics for patents related to the oral GLP-1 drug CT-996, aiming to protect its obesity pipeline from patent litigation. The deal includes low-single-digit royalties on future sales. Roche's CT-996 showed promising early-stage weight loss results, while Structure's aleniglipron is also advancing in trials.
Jan 6, 2026
Novo Nordisk is set to launch a more affordable alternative to Ozempic amid ongoing delays with generic versions.
Health Canada has received nine applications from five companies to sell generic versions of semaglutide, the active ingredient in Novo Nordisk's Ozempic. While generics are now legal, none have been approved yet. Novo Nordisk plans to introduce new versions, Plosbrio and Poviztra, to compete in the market. The delay in approvals is raising concerns about high drug costs for patients.
Jan 6, 2026
Lilly re-engages with Nimbus in a $1.3 billion agreement to develop a new oral medication for obesity - Fierce Biotech
Eli Lilly has partnered with Nimbus Therapeutics for a new collaboration focused on oral obesity therapies, committing up to $55 million in upfront payments. The partnership aims to develop a novel oral treatment for obesity and metabolic diseases, potentially leading to $1.3 billion in future milestone payments. This follows a previous $496 million deal for targeted therapies in metabolic diseases.
Jan 6, 2026
JNJ vs. AZN: Which Pharmaceutical Stock is the Better Investment? - TradingView
Johnson & Johnson (JNJ) and AstraZeneca (AZN) are major players in the pharmaceutical industry, both showing strong growth in 2025. JNJ's diversified portfolio and innovative drugs like Darzalex and Stelara position it well, despite challenges from patent expirations and legal issues. AZN, with blockbuster drugs like Tagrisso and Farxiga, also faces competition and regulatory hurdles. Analysts favor JNJ for its stability and consistent dividend growth.
Jan 6, 2026
US authorities authorize Wegovy pill for weight management - The Philadelphia Sunday Sun
U.S. regulators have approved Novo Nordisk's oral version of Wegovy, a weight-loss drug containing semaglutide, making it the first daily pill for obesity treatment. This approval gives Novo Nordisk an advantage over Eli Lilly's orforglipron, still under review. The Wegovy pill, expected to be available soon, aims to broaden access and reduce costs for obesity treatments.
Jan 5, 2026
Publicly-Financed Research Reveals Generic Medications Are Comparable to Brand-Name Drugs in Quality, Yet More Affordable...
A citizen-funded study in India has found that generic medicines match the quality of branded drugs but can cost up to 14 times less. This initiative challenges existing skepticism about generics and highlights significant price disparities in the pharmaceutical market. The findings support the Pradhan Mantri Bhartiya Janaushadhi Pariyojana program.
Jan 5, 2026
Should You Consider Selling Your Eli Lilly Stocks? | The Motley Fool
Eli Lilly leads the GLP-1 drug market, but Novo Nordisk's recent introduction of a pill delivery method could shift the dynamics. Eli Lilly's stock has risen significantly, while Novo Nordisk's has declined. Investors may consider selling Eli Lilly due to its high valuation and explore Novo Nordisk or Pfizer, which is also pursuing GLP-1 innovations.
Jan 5, 2026
Swift Implementation with Operational Excellence - Pharmaceutical Technology
In 2025, the pharmaceutical industry faced challenges like supply chain security and market demand, influenced by tariffs and geopolitical unrest. Meri Beckwith, Co-CEO of Lindus Health, noted a shift towards treating clinical operations as strategic, with AI enhancing efficiency. Looking to 2026, AI integration and real-world evidence will drive innovation in drug development, emphasizing patient-centric models and operational excellence.
Jan 5, 2026
Jiangsu Simcere Pharmaceutical unveils novel antibody-drug conjugates - BioWorld
Jiangsu Simcere Pharmaceutical Co. Ltd. has announced the development of new antibody-drug conjugates (ADCs) designed for the treatment of atopic dermatitis. These ADCs consist of antibody or antigen-binding fragments connected to a cytotoxic drug via a linker, showcasing potential advancements in dermatologic therapies.
Jan 5, 2026
The Future of Ozempic and Other GLP-1 Medications: What to Expect by 2026
Investors are closely monitoring GLP-1 drugs like Ozempic and Mounjaro, as the market is projected to expand significantly by 2026. Major players Novo Nordisk and Eli Lilly are advancing next-generation therapies, while companies like AstraZeneca and Pfizer are also entering the space. The industry faces challenges from competition and regulatory concerns, but opportunities for growth remain as new formulations emerge.
Jan 5, 2026
Three key topics to monitor in the biopharmaceutical industry in 2026 - STAT News
In 2026, the pharmaceutical industry faces significant challenges as Americans demand affordable medicines. The complexities of drug development and healthcare insurance complicate efforts to ensure competition and lower costs. Key issues will emerge as the Trump administration attempts to fulfill its promise to reduce medicine prices, making this year pivotal for the industry.
Jan 5, 2026
Wegovy's initial dosage is now offered in a daily pill form rather than through a weekly injection - WRAL
Novo Nordisk has launched the oral version of its weight-loss drug Wegovy, available in a 1.5 mg starter dose for $149 monthly. The pill, which contains semaglutide, offers a more affordable option compared to the injectable version. Eli Lilly is also developing a competing oral GLP-1 medication, orforglipron, expected to be approved soon.
Jan 5, 2026
UP FSDA Introduces Stringent New Regulations for Wholesale Drug Licenses to Address Irregularities
The Uttar Pradesh Food Safety and Drug Administration (FSDA) has introduced stringent new guidelines for wholesale drug licenses to combat irregularities in the pharmaceutical sector. This initiative aims to enhance regulatory oversight and prevent the misuse of drugs, reflecting the government's commitment to ensuring drug safety and compliance.
Jan 5, 2026
Pharmaceuticals, mortality rates, and professional ethics - The Island
Sri Lanka faces increasing climatic hazards, particularly from cyclones like Ditwah, which caused an estimated $4.1 billion in damages. The country must enhance environmental literacy and awareness to mitigate risks associated with floods and landslides. Experts emphasize the need for data-driven strategies and educational reforms to address changing rainfall patterns and promote sustainable practices.
Jan 5, 2026
Expiration of Generic Semaglutide patent presents a potential market opportunity exceeding Rs 50,000 Crore for pharmaceutical companies, according to a report.
The patent expiry of semaglutide drugs is projected to create a revenue opportunity exceeding Rs 50 billion for generic manufacturers in India and select markets like Canada and Brazil. Companies such as Alkem Laboratories, Dr. Reddy's Laboratories, and Sun Pharma are poised to benefit, with potential price reductions of 30-75%. Analysts emphasize the importance of regulatory approvals for success.
Jan 5, 2026
Merck & Co. Inc.: The Transformation of a 130-Year-Old Pharmaceutical Leader Focusing on Cancer Treatment
Merck & Co. Inc. is transforming from reliance on its blockbuster drug Keytruda into a diversified product platform focusing on oncology, vaccines, and advanced R&D. The company aims to build a resilient ecosystem through strategic acquisitions and data-driven approaches, enhancing its competitive edge against rivals like Pfizer and Bristol Myers Squibb. Keytruda remains central to this strategy, supported by vaccines like Gardasil.
Jan 4, 2026
Several States Report Confiscations and Breaches Involving Cough Syrups, Tablets, and Rehabilitation Facilities
A recent crackdown in India has revealed a significant rise in the illegal trade and misuse of narcotic drugs, particularly codeine-based cough syrups and banned tablets. Multiple states are reporting increased seizures and violations, highlighting a growing crisis in drug misuse and the challenges faced by de-addiction centers.
